pBabe EGFR(L858R/T790M) Citations (8)

Originally described in: Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors.
Yuza Y, Glatt KA, Jiang J, Greulich H, Minami Y, Woo MS, Shimamura T, Shapiro G, Lee JC, Ji H, Feng W, Chen TH, Yanagisawa H, Wong KK, Meyerson M Cancer Biol Ther. 2007 May . 6(5):661-7. PubMed Journal

---

Articles Citing pBabe EGFR(L858R/T790M)

Articles
AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells. Ku BM, Bae YH, Koh J, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Invest New Drugs. 2016 Aug;34(4):407-15. doi: 10.1007/s10637-016-0350-y. Epub 2016 Apr 5. PubMed
A novel multi-target inhibitor harboring selectivity of inhibiting EGFR T790M sparing wild-type EGFR. Song X, Qi X, Wang Q, Zhu W, Li J. Am J Cancer Res. 2017 Sep 1;7(9):1884-1898. eCollection 2017. PubMed
FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy. Quintanal-Villalonga A, Molina-Pinelo S, Cirauqui C, Ojeda-Marquez L, Marrugal A, Suarez R, Conde E, Ponce-Aix S, Enguita AB, Carnero A, Ferrer I, Paz-Ares L. J Thorac Oncol. 2019 Apr;14(4):641-655. doi: 10.1016/j.jtho.2018.12.021. Epub 2019 Jan 9. PubMed
FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective. Quintanal-Villalonga A, Molina-Pinelo S, Yague P, Marrugal A, Ojeda-Marquez L, Suarez R, Ponce-Aix S, Enguita AB, Carnero A, Ferrer I, Paz-Ares L. Lung Cancer. 2019 May;131:112-121. doi: 10.1016/j.lungcan.2019.02.007. Epub 2019 Feb 8. PubMed
Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor. Nishiya N, Oku Y, Ishikawa C, Fukuda T, Dan S, Mashima T, Ushijima M, Furukawa Y, Sasaki Y, Otsu K, Sakyo T, Abe M, Yonezawa H, Ishibashi F, Matsuura M, Tomida A, Seimiya H, Yamori T, Iwao M, Uehara Y. Cancer Sci. 2021 May;112(5):1963-1974. doi: 10.1111/cas.14839. Epub 2021 Mar 24. PubMed
Single-cell analyses reveal YAP/TAZ as regulators of stemness and cell plasticity in Glioblastoma. Castellan M, Guarnieri A, Fujimura A, Zanconato F, Battilana G, Panciera T, Sladitschek HL, Contessotto P, Citron A, Grilli A, Romano O, Bicciato S, Fassan M, Porcu E, Rosato A, Cordenonsi M, Piccolo S. Nat Cancer. 2021 Feb;2(2):174-188. doi: 10.1038/s43018-020-00150-z. Epub 2020 Dec 7. PubMed
FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatment. Song X, Tang W, Peng H, Qi X, Li J. Invest New Drugs. 2021 Oct;39(5):1201-1212. doi: 10.1007/s10637-021-01061-1. Epub 2021 Apr 7. PubMed
Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention. Pan J, Xiong D, Zhang Q, Palen K, Shoemaker RH, Johnson B, Sei S, Wang Y, You M. Front Immunol. 2023 Feb 17;14:1036563. doi: 10.3389/fimmu.2023.1036563. eCollection 2023. PubMed

If you have published an article using this material, please email us at to have your article added to this page.